Literature DB >> 10328137

Inhibitors of tumor necrosis factor for rheumatoid arthritis.

L W Moreland1.   

Abstract

Clinical trials of tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) have produced consistently outstanding results with no major side effects in patients refractory to other available treatments. The improvement, determined using either the Paulus or the American College of Rheumatology evaluation criteria, is rapid and has persisted over the 2 years of followup data currently available. Trials of 2 drugs are reviewed--infliximab, currently approved for treatment of Crohn's disease, and etanercept, recently approved for RA therapy.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10328137

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN： 0380-0903


  13 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors.

Authors:  L Berg; J Lampa; S Rogberg; R van Vollenhoven ; L Klareskog
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

Review 4.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.

Authors:  C K Edwards
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

5.  MSC Therapeutics in Chronic Inflammation.

Authors:  Alex Sargent; Robert H Miller
Journal:  Curr Stem Cell Rep       Date:  2016-03-29

6.  Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.

Authors:  P H Carter; P A Scherle; J K Muckelbauer; M E Voss; R Q Liu; L A Thompson; A J Tebben; K A Solomon; Y C Lo; Z Li; P Strzemienski; G Yang; N Falahatpisheh; M Xu; Z Wu; N A Farrow; K Ramnarayan; J Wang; D Rideout; V Yalamoori; P Domaille; D J Underwood; J M Trzaskos; S M Friedman; R C Newton; C P Decicco; J A Muckelbauer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

Review 7.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Tumour necrosis factor-alpha (TNF-alpha) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice.

Authors:  S Wahid; M C Blades; D De Lord; I Brown; G Blake; G Yanni; D O Haskard; G S Panayi; C Pitzalis
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

9.  The in vivo effects of tumour necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis.

Authors:  K A Bush; B W Kirkham; J S Walker
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

10.  Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.

Authors:  Shuaiyi Liang; Jianxin Dai; Sheng Hou; Lishu Su; Dapeng Zhang; Huaizu Guo; Shi Hu; Hao Wang; Zihe Rao; Yajun Guo; Zhiyong Lou
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.